HIV Coinfection Is Associated with Low-Fitness

Antitubercular Agents Bacterial Proteins / genetics DNA-Directed RNA Polymerases / genetics HIV Infections / complications Humans Microbial Sensitivity Tests Mutation Mycobacterium tuberculosis / genetics Rifampin Tuberculosis, Multidrug-Resistant
HIV-TB coinfection Mycobacterium tuberculosis drug resistance fitness cost rifampicin

Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
21 09 2020
Historique:
received: 23 04 2020
accepted: 23 07 2020
pubmed: 29 7 2020
medline: 22 6 2021
entrez: 29 7 2020
Statut: epublish

Résumé

We analyzed 312 drug-resistant genomes of

Identifiants

DOI: 10.1128/AAC.00782-20 PMID: 32718966 PMC: PMC7508592
pubmed: 32718966
pii: AAC.00782-20
doi: 10.1128/AAC.00782-20
pmc: PMC7508592
pii:
doi:

Substances chimiques

Antitubercular Agents 0
Bacterial Proteins 0
DNA-Directed RNA Polymerases EC 2.7.7.6
Rifampin VJT6J7R4TR

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Wellcome Trust
ID : 203135
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : U01 AI096299
Pays : United States
Organisme : Wellcome Trust
ID : 104803
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : U01 AI069911
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069907
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : U01 AI069924
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069923
Pays : United States
Organisme : NIAID NIH HHS
ID : R24 AI124872
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069919
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069918
Pays : United States

Informations de copyright

Copyright © 2020 Loiseau et al.

Références

Lancet. 2006 Nov 4;368(9547):1575-80
pubmed: 17084757
Mol Biol Evol. 2020 Jan 1;37(1):195-207
pubmed: 31532481
J Infect Dis. 2000 Dec;182(6):1788-90
pubmed: 11069256
PLoS One. 2014 Jan 08;9(1):e82235
pubmed: 24416139
Am J Respir Crit Care Med. 2014 Jun 1;189(11):1426-34
pubmed: 24786895
Clin Infect Dis. 2014 Mar;58(6):765-74
pubmed: 24368620
Science. 2002 Mar 15;295(5562):2042-6
pubmed: 11896268
Int J Tuberc Lung Dis. 2009 Dec;13(12):1456-66
pubmed: 19919762
Nat Med. 2004 Oct;10(10):1117-21
pubmed: 15378056
J Infect Dis. 2007 Aug 15;196 Suppl 1:S86-107
pubmed: 17624830
PLoS Med. 2009 Feb 10;6(2):e2
pubmed: 19209951
Elife. 2016 Aug 09;5:
pubmed: 27502557
Int J Tuberc Lung Dis. 2017 May 1;21(5):531-536
pubmed: 28399968
PLoS One. 2009;4(5):e5561
pubmed: 19440304
Antimicrob Agents Chemother. 1999 Aug;43(8):1866-9
pubmed: 10428904
Nat Commun. 2015 May 11;6:7119
pubmed: 25960343
Mol Microbiol. 2014 Mar;91(6):1106-19
pubmed: 24417450
Nat Genet. 2011 Dec 18;44(1):106-10
pubmed: 22179134
Proc Biol Sci. 2016 May 11;283(1830):
pubmed: 27170722
Mol Microbiol. 1995 Jan;15(2):235-45
pubmed: 7746145
Nat Genet. 2014 Mar;46(3):279-86
pubmed: 24464101
Antimicrob Agents Chemother. 2002 May;46(5):1204-11
pubmed: 11959546
PLoS Pathog. 2006 Jun;2(6):e61
pubmed: 16789833
Antimicrob Agents Chemother. 2004 Apr;48(4):1289-94
pubmed: 15047531
Genome Res. 2012 Apr;22(4):735-45
pubmed: 22294518
Int J Epidemiol. 2012 Oct;41(5):1256-64
pubmed: 21593078
Expert Rev Respir Med. 2009 Feb;3(1):67-79
pubmed: 20477283
Clin Infect Dis. 2010 May 15;50 Suppl 3:S201-7
pubmed: 20397949
Lancet Infect Dis. 2019 Mar;19(3):e77-e88
pubmed: 30554996
Science. 2006 Jun 30;312(5782):1944-6
pubmed: 16809538
Clin Microbiol Rev. 2011 Apr;24(2):351-76
pubmed: 21482729
Lancet Infect Dis. 2019 Mar;19(3):298-307
pubmed: 30744962
Mol Microbiol. 2010 Aug;77(4):830-40
pubmed: 20545852
Antimicrob Agents Chemother. 2013 Feb;57(2):827-32
pubmed: 23208709
Int J Epidemiol. 2007 Oct;36(5):969-76
pubmed: 17846055
Infect Immun. 2002 Sep;70(9):4955-60
pubmed: 12183541

Auteurs

Chloé Loiseau (C)

Swiss Tropical and Public Health Institute, Basel, Switzerland.
University of Basel, Basel, Switzerland.

Daniela Brites (D)

Swiss Tropical and Public Health Institute, Basel, Switzerland.
University of Basel, Basel, Switzerland.

Miriam Reinhard (M)

Swiss Tropical and Public Health Institute, Basel, Switzerland.
University of Basel, Basel, Switzerland.

Kathrin Zürcher (K)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

Sonia Borrell (S)

Swiss Tropical and Public Health Institute, Basel, Switzerland.
University of Basel, Basel, Switzerland.

Marie Ballif (M)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

Lukas Fenner (L)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
ORCID: 0000-0003-3309-4835

Helen Cox (H)

Institute of Infectious Disease and Molecular Medicine and Wellcome Centre for Infectious Disease Research in Africa, University of Cape Town, Cape Town, South Africa.

Liliana K Rutaihwa (LK)

Swiss Tropical and Public Health Institute, Basel, Switzerland.
University of Basel, Basel, Switzerland.
Ifakara Health Institute, Bagamoyo, Tanzania.

Robert J Wilkinson (RJ)

Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Observatory, South Africa.
Department of Infectious Diseases, Imperial College London, London, United Kingdom.
Francis Crick Institute, London, United Kingdom.

Marcel Yotebieng (M)

Division of General Internal Medicine, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.

E Jane Carter (EJ)

Department of Medicine, Moi University School of Medicine, and Moi Teaching and Referral Hospital, Eldoret, Kenya.

Alash'le Abimiku (A)

Institute of Human Virology, Abuja, Nigeria.

Olivier Marcy (O)

Centre de Prise en Charge de Recherche et de Formation, Yopougon, Abidjan, Côte d'Ivoire.
Bordeaux Population Health Research Center, Inserm U1219, University of Bordeaux, Bordeaux, France.

Eduardo Gotuzzo (E)

TB Research Unit, Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.

Anchalee Avihingsanon (A)

The HIV Netherlands Australia Thailand (HIV-NAT) Research Collaboration, Thai Red Cross AIDS Research Centre and Tuberculosis Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

Nicola Zetola (N)

University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Basra Doulla (B)

Central Tuberculosis Reference Laboratory, Dar es Salaam, Tanzania.
National Tuberculosis and Leprosy Programme, Dar es Salaam, Tanzania.

Erik C Böttger (EC)

Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland.
Swiss National Center for Mycobacteria, Zurich, Switzerland.

Matthias Egger (M)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Centre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

Sebastien Gagneux (S)

Swiss Tropical and Public Health Institute, Basel, Switzerland sebastien.gagneux@swisstph.ch.
University of Basel, Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Antituberculeux › HIV Coinfection Is Associated with Low-Fitness
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines bactériennes › HIV Coinfection Is Associated with Low-Fitness
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Transferases › Phosphotransferases › Nucleotidyltransferases › RNA nucleotidyltransferases › DNA-directed RNA polymerases › HIV Coinfection Is Associated with Low-Fitness
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › HIV Coinfection Is Associated with Low-Fitness
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › HIV Coinfection Is Associated with Low-Fitness
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de sensibilité microbienne › HIV Coinfection Is Associated with Low-Fitness
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › HIV Coinfection Is Associated with Low-Fitness
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Bâtonnets à Gram positif › Bâtonnets asporogènes à Gram positif › Bâtonnets asporogènes réguliers à Gram positif › Mycobacteriaceae › Mycobacterium › Mycobacterium tuberculosis › HIV Coinfection Is Associated with Low-Fitness
questionsmedicales.fr › Composés polycycliques › Composés macrocycliques › Lactames macrocycliques › Rifamycine › Rifampicine › HIV Coinfection Is Associated with Low-Fitness
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram positif › Infections à Actinomycetales › Infections à Mycobacterium › Tuberculose › Tuberculose multirésistante › HIV Coinfection Is Associated with Low-Fitness